October 03, 2017
Targovax granted US Patent for mutant-RAS neoantigen platform 2nd generation product TG02
Media
October 03, 2017
Strongbridge Biopharma plc Announces Proposed Public Offering of Ordinary Shares
October 02, 2017
GenSight Biologics integrates the Enternext PEA-PME 150 index
October 02, 2017
Onxeo Introduces platON™, a Proprietary Chemistry Platform of Decoy Oligonucleotides
October 02, 2017
Orexo signs asset purchase agreement with Gesynta Pharma AB for OX-MPI
October 01, 2017
Promising preliminary long-term data from WTX101 Phase 2 extension study to be presented at AASLD Annual Meeting
September 28, 2017
Onxeo announces compelling preclinical data in combination for its two innovative compounds, AsiDNA™ and belinostat
September 25, 2017
Strongbridge Biopharma plc Launches the Uncovering Periodic Paralysis Genetic Testing Program
September 25, 2017
Fusion Pharmaceuticals Completes Oversubscribed Series A Financing Totaling $46 Million USD to Develop Targeted Alpha Therapeutics
September 25, 2017
Targovax granted US Patent for mutant-RAS neoantigen platform lead products